Hai Zemmour

Hai Zemmour

Auto-generated profile, based on publicly available information

Hai Zemmour

Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJoshua Moss
Joshua Moss
JMJudith Magenheim
Judith Magenheim
DNDaniel Neiman
Daniel Neiman
HZHai Zemmour
Hai Zemmour
NLNetanel Loyfer
Netanel Loyfer
YDYuval Dor
Yuval Dor
Methylation patterns of circulating cell-free DNA (cfDNA) contain rich information about recent cell death events in the body. Here, we present an approach for unbiased determination of the tissue origins of cfDNA, using a reference methylation atlas of 25 human tissues and cell types. The method is validated using in silico simulations as well as in vitro mixes of DNA from different tissue sources at known proportions. We show that plasma cfDNA of healthy donors originates from white blood cells (55%), erythrocyte progenitors (30%), vascular endothelial cells (10%) and hepatocytes (1%). Deconvolution of cfDNA from patients reveals tissue contributions that agree with clinical findings in sepsis, islet transplantation, cancer of the colon, lung, breast and prostate, and cancer of unknown primary. We propose a procedure which can be easily adapted to study the cellular contributors to cfDNA in many settings, opening a broad window into healthy and pathologic human tissue dynamics.

24 April 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
HZHai Zemmour
Hai Zemmour
DPDavid Planer
David Planer
JMJudith Magenheim
Judith Magenheim
JMJoshua Moss
Joshua Moss
DNDaniel Neiman
Daniel Neiman
YDYuval Dor
Yuval Dor
Detection of cardiomyocyte death is crucial for the diagnosis and treatment of heart disease. Here we use comparative methylome analysis to identify genomic loci that are unmethylated specifically in cardiomyocytes, and develop these as biomarkers to quantify cardiomyocyte DNA in circulating cell-free DNA (cfDNA) derived from dying cells. Plasma of healthy individuals contains essentially no cardiomyocyte cfDNA, consistent with minimal cardiac turnover. Patients with acute ST-elevation myocardial infarction show a robust cardiac cfDNA signal that correlates with levels of troponin and creatine phosphokinase (CPK), including the expected elevation-decay dynamics following coronary angioplasty. Patients with sepsis have high cardiac cfDNA concentrations that strongly predict mortality, suggesting a major role of cardiomyocyte death in mortality from sepsis. A cfDNA biomarker for cardiomyocyte death may find utility in diagnosis and monitoring of cardiac pathologies and in the study of normal human cardiac physiology and development.

21 June 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
RLRoni Lehmann-Werman
Roni Lehmann-Werman
JMJudith Magenheim
Judith Magenheim
JMJoshua Moss
Joshua Moss
DNDaniel Neiman
Daniel Neiman
OAOfri Abraham
Ofri Abraham
YDYuval Dor
Yuval Dor
Liver damage is typically inferred from serum measurements of cytoplasmic liver enzymes. DNA molecules released from dying hepatocytes are an alternative biomarker, unexplored so far, potentially allowing for quantitative assessment of liver cell death. Here we describe a method for detecting acute hepatocyte death, based on quantification of circulating, cell-free DNA (cfDNA) fragments carrying hepatocyte-specific methylation patterns. We identified 3 genomic loci that are unmethylated specifically in hepatocytes, and used bisulfite conversion, PCR, and massively parallel sequencing to quantify the concentration of hepatocyte-derived DNA in mixed samples. Healthy donors had, on average, 30 hepatocyte genomes/ml plasma, reflective of basal cell turnover in the liver. We identified elevations of hepatocyte cfDNA in patients shortly after liver transplantation, during acute rejection of an established liver transplant, and also in healthy individuals after partial hepatectomy. Furthermore, patients with sepsis had high levels of hepatocyte cfDNA, which correlated with levels of liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Duchenne muscular dystrophy patients, in which elevated AST and ALT derive from damaged muscle rather than liver, did not have elevated hepatocyte cfDNA. We conclude that measurements of hepatocyte-derived cfDNA can provide specific and sensitive information on hepatocyte death, for monitoring human liver dynamics, disease, and toxicity.

25 January 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
ALAsael Lubotzky
Asael Lubotzky
HZHai Zemmour
Hai Zemmour
DNDaniel Neiman
Daniel Neiman
MGMarc Gotkine
Marc Gotkine
NLNetanel Loyfer
Netanel Loyfer
YDYuval Dor
Yuval Dor
Cancer inflicts damage to surrounding normal tissues, which can culminate in fatal organ failure. Here, we demonstrate that cell death in organs affected by cancer can be detected by tissue-specific methylation patterns of circulating cell-free DNA (cfDNA). We detected elevated levels of hepatocyte-derived cfDNA in the plasma of patients with liver metastases originating from different primary tumors, compared with cancer patients without liver metastases. In addition, patients with localized pancreatic or colon cancer showed elevated hepatocyte cfDNA, suggesting liver damage inflicted by micrometastatic disease, by primary pancreatic tumor pressing the bile duct, or by a systemic response to the primary tumor. We also identified elevated neuron-, oligodendrocyte-, and astrocyte-derived cfDNA in a subpopulation of patients with brain metastases compared with cancer patients without brain metastasis. Cell type–specific cfDNA methylation markers enable the identification of collateral tissue damage in cancer, revealing the presence of metastases in specific locations and potentially assisting in early cancer detection.

28 November 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CMChen Makranz
Chen Makranz
ALAsael Lubotzky
Asael Lubotzky
HZHai Zemmour
Hai Zemmour
RSRuth Shemer
Ruth Shemer
BGBenjamin Glaser
Benjamin Glaser
AZAviad Zick
Aviad Zick
Background: Radiotherapy has an important role in the treatment of brain metastases but carries risk of short and/or long-term toxicity, termed radiation-induced brain injury (RBI). As the diagnosis of RBI is crucial for correct patient management, there is an unmet need for reliable biomarkers for RBI. The aim of this proof-of concept study is to determine the utility of brain-derived circulating free DNA (BncfDNA), identified by specific methylation patterns for neurons, astrocytes, and oligodendrocytes, as biomarkers brain injury induced by radiotherapy. Methods: Twenty-four patients with brain metastases were monitored clinically and radiologically before, during and after brain radiotherapy, and blood for BncfDNA analysis (98 samples) was concurrently collected. Sixteen patients were treated with whole brain radiotherapy and eight patients with stereotactic radiosurgery. Results: During follow-up nine RBI events were detected, and all correlated with significant increase in BncfDNA levels compared to baseline. Additionally, resolution of RBI correlated with a decrease in BncfDNA. Changes in BncfDNA were independent of tumor response. Conclusions: Elevated BncfDNA levels reflects brain cell injury incurred by radiotherapy. further research is needed to establish BncfDNA as a novel plasma-based biomarker for brain injury induced by radiotherapy.

HAHiba Abuelhija
Hiba Abuelhija
AMAsaf Mandel
Asaf Mandel
SWSalmas Watad
Salmas Watad
HZHai Zemmour
Hai Zemmour
EKEitan Keizman
Eitan Keizman
UPUri Pollak
Uri Pollak
Circulating cell-free DNA (cfDNA) is released during tissue injury and systemic inflammation, but its association with postoperative organ injury following pediatric cardiac surgery remains incompletely defined. We evaluated the relationship between early postoperative cfDNA levels and acute kidney injury (AKI) and biochemical hepatic injury in children undergoing open-heart surgery with cardiopulmonary bypass (CPB). This retrospective observational cohort study included 50 pediatric patients (<18 years) who underwent CPB at a tertiary congenital heart center between 2017 and 2018. Plasma cfDNA concentrations were measured perioperatively, with the 6 h postoperative value analyzed as an early biomarker window. AKI was classified using Kidney Disease: Improving Global Outcomes criteria, and hepatic injury was assessed using serial liver enzyme measurements. cfDNA levels increased significantly within 6 h after CPB and were higher in patients with more severe AKI. Six-hour cfDNA concentrations correlated with postoperative creatinine, urea, alanine aminotransferase, and aspartate aminotransferase. In multivariable regression analyses adjusting for cardiopulmonary bypass duration, aortic cross-clamp time, and preoperative oxygen saturation, cfDNA at 6 h remained independently associated with AKI severity and peak liver enzyme levels. These exploratory findings suggest that early postoperative cfDNA elevation is associated with AKI severity and biochemical hepatic injury after pediatric cardiac surgery with CPB. Larger prospective studies are needed to determine its independent predictive value and clinical utility.